The veterinary product has a pronounced effect on RNA-containing viruses of the families Paramyxoviridae, Coronaviridae, Arenaviridae, Retroviridae, Picornaviridae, Birnaviridae, Orthomyxoviridae, etc.
The mechanism of action is based on the damage of RNA viral particles using a low molecular weight artificial ribonuclease. High stability to physical and chemical factors, as well as the small size of artificial RNase in comparison with protein molecules, provide high efficiency of antiviral therapy. The small molecular weight of the compound increases the efficiency of penetration of synthetic ribonuclease into the virus capsid and high chemical and temperature stability provides the possibility of oral administration of the antiviral veterinary product.
The veterinary product is not toxic, no contraindications were found.
The veterinary product, according to the degree of exposure belongs to moderate-hazard substances (hazard class 3 according to GOST 12.1.007-76).